- Deferasirox
routes of administration Oral licence EU Exjade license US Deferasirox Deferasirox marketed as Exjade ... Choudhry VP, Naithani R title Current status of iron overload and chelation with deferasirox journal ... Deferasirox a review of its use in the management of transfusional chronic iron overload journal Drugs ... deferasirox oral suspension tablets. Properties of deferasirox Image Deferasirox iron III complex.png thumb left Two deferasirox molecules binding iron The half life of deferasirox is between 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to 1 atom ... route intravenous infusion . Together with deferiprone , deferasirox seems to be capable of removing ... Deferasirox can be prepared from simple commercially available starting materials salicylic acid, salicylamide and 4 hydrazinobenzoic acid in the following two step synthetic sequence Image Deferasirox ... triazol 1 yl benzoic acid Deferasirox . ref name Steinhauser cite journal author Stefan Steinhauser ... ref Risks Deferasirox was the 2 drug on the list of Most frequent suspected drugs in reported patient ... more details
|
- File:Deferasirox synthesis.png
Summary Synthesis of Deferasirox Licensing PD self date December 2009 ... more details
|
- Transfusion hemosiderosis
Infobox Disease Name PAGENAME Image Caption DiseasesDB ICD10 ICD10 T 80 8 t 80 ICD9 ICD9 999.8 ICDO OMIM MedlinePlus eMedicineSubj eMedicineTopic MeshID Transfusional hemosiderosis is the accumulation of iron in the liver and or heart but also endocrine organs, in patients who receive frequent blood transfusion s such as those with thalassemia , sickle cell disease , aplastic anemia or myelodysplastic syndrome . Treatment Treatment is by iron chelating agent s deferoxamine , ref name pmid18360637 cite journal author Cappellini MD title Exjade R deferasirox, ICL670 in the treatment of chronic iron overload associated with blood transfusion journal Ther Clin Risk Manag volume 3 issue 2 pages 291 9 year 2007 month June pmid 18360637 doi 10.2147 tcrm.2007.3.2.291 url pmc 1936310 ref deferiprone or deferasirox . If iron overload has caused end organ damage, this is generally irreversible and may require Organ transplant transplantation . Notable patients Ted DeVita , the bubble boy , died of transfusional iron overload from too many blood transfusion s. See also Hemosiderosis References reflist medical stub Complications of surgical and medical care Category Hematology Category Complications of surgical and medical care ... more details
|
- ATC code V03
ATC codes lead V 03 All other therapeutic products vet add anchor V03A V03A All other therapeutic products anchor V03AB V03AB Antidote s V03AB01 Ipecacuanha V03AB02 Nalorphine V03AB03 Edetates V03AB04 Pralidoxime V03AB05 Prednisolone and promethazine V03AB06 Thiosulfate V03AB08 Sodium nitrite V03AB09 Dimercaprol V03AB13 Obidoxime V03AB14 Protamine V03AB15 Naloxone V03AB16 Ethanol V03AB17 Methylthioninium chloride V03AB18 Potassium permanganate V03AB19 Physostigmine V03AB20 Copper sulfate V03AB21 Potassium iodide V03AB22 Amyl nitrite V03AB23 Acetylcysteine V03AB24 Digitalis antitoxin V03AB25 Flumazenil V03AB26 Methionine V03AB27 4 dimethylaminophenol V03AB29 Cholinesterase V03AB31 Prussian blue V03AB32 Glutathione V03AB33 Hydroxocobalamin V03AB34 Fomepizole V03AB35 Sugammadex V03AB36 Phentolamine QV03AB90 Atipamezole QV03AB91 Sarmazenil QV03AB92 Diprenorfin QV03AB93 Yohimbine QV03AB94 Tolazoline anchor V03AC V03AC Iron chelating agent s V03AC01 Deferoxamine V03AC02 Deferiprone V03AC03 Deferasirox anchor V03AE V03AE Drugs for treatment of hyperkalemia and hyperphosphatemia V03AE01 Polystyrene sulfonate V03AE02 Sevelamer V03AE03 Lanthanum carbonate V03AE04 Calcium acetate and magnesium carbonate anchor V03AF V03AF Detoxifying agents for antineoplastic treatment V03AF01 Mesna V03AF02 Dexrazoxane V03AF03 Calcium folinate V03AF04 Calcium levofolinate V03AF05 Amifostine V03AF06 Sodium folinate V03AF07 Rasburicase V03AF08 Palifermin V03AF09 Glucarpidase V03AF10 Sodium levofolinate anchor V03AG V03AG Drugs for treatment of hypercalcemia V03AG01 Sodium cellulose phosphate anchor V03AH V03AH Drugs for treatment of hypoglycaemia V03AH01 Diazoxide anchor V03AK V03AK Tissue adhesives anchor V03AM V03AM Drugs for embolisation anchor V03AN V03AN Medical gases V03AN01 Oxygen V03AN02 Carbon dioxide V03AN03 Helium V03AN04 Nitrogen V03AN05 Medical air anchor V03AX V03AX Other therapeutic products V03AX02 Nalfurafine anchor V03AZ V03AZ Nerve depressants V03AZ01 Ethanol References Reflis ... more details
|
- Congenital dyserythropoietic anemia
Congenital dyserythropoietic anemia CDA is a rare blood disorder, similar to the thalassemias. CDA is transmitted by both parents autosomal recessively, and affects the size and shape of the red blood cell s formed in the offspring, particularly the amount of hemoglobin that is carried. Congenital dyserythropoietic anemia has over four different subtypes, but CDA Type I, CDA Type II, CDA Type III, and CDA Type IV are the most common. CDA type II CDA II is the most frequent type of congenital dyserythropoietic anemias. More than 200 cases have been described, but with the exception of a report by the International CDA II Registry, these reports include only small numbers of cases and no data on the lifetime evolution of the disease. ref http bloodjournal.hematologylibrary.org cgi content abstract 102 13 4576 ref Patients with CDA typically get frequent blood transfusion s, but this can vary depending on the type that is acquired. Patients typically report going every 3 5 weeks for blood transfusions, and receive somewhere between 1 2 adult units of blood 3 4 child units for children . In addition, they must undertake chelation therapy to survive either deferoxamine i.e . Desferal , deferasirox i.e. Exjade , or deferiprone i.e. Kelfer, Ferriprox to eliminate the excess iron that accumulates with lifelong transfusions. In a clinical sense, the disorder is very similar to thalassemia major Thalassemia Beta thalassemia and treated in the same fashion. Removal of the spleen and gallbladder are common, and problems with the liver and heart become increasingly important as the individual ages, due to stresses from low hemoglobin counts and high iron content. Hemoglobin levels usually run anywhere between 6.0 gm dl and 7.0 gm dl in untransfused patients, and between 8.0 gm dl and 10.0 gm dl in well transfused patients. It is important to go regularly for transfusions and to chelate daily in order to maximize good health. Exjade, an oral chelator approved by the FDA in Novemb ... more details
|
- Myelodysplastic syndrome
two iron chelators available in the US, deferoxamine Desferal for IV use and deferasirox ... deferasirox is generally well tolerated other than episodes of gastrointestinal distress and kidney ... to deferasirox treatment guidelines. Following post marketing use of deferasirox, there were rare cases ... that patients be closely monitored on deferasirox therapy prior to the start of therapy and regularly ... of deferasirox to placebo, which should help to establish the clinical value of deferasirox in iron ... more details
|
- Khashayar Karimian
of Deferasirox and Deferiprone on Nickel Oxyhydroxide midified Electrode , Anal. Biochem., 2007 ..., H. Moosavi Movahedi, A.A. Shafiee, A. Karimian, K. Electrocatalytic oxidation and determination of deferasirox ..., A. A. The Effects of Deferiprone and Deferasirox on the Structure and Function of b Thalassemia ... more details
|
- Deferiprone
Full Text . ref See also Deferoxamine Deferasirox References references Chelating agents Category Chelating ... more details
|
- Chelation therapy
os 1998 12 9623147att.htm notification letter ref Medical use Image Deferasirox iron III complex.png thumb 275px Two molecules of deferasirox , an orally administered chelator, binding iron . Deferasirox ... ref name KatzungTrevor2008 Deferoxamine and Deferasirox acute iron poisoning ref name KatzungTrevor2008 ... more details
|
- List of drugs: De
List of drugs D De de dea deb deanol aceglumate International Nonproprietary Name INN Deapril ST deboxamet International Nonproprietary Name INN debrisoquine International Nonproprietary Name INN debropol International Nonproprietary Name INN dec def Deca Durabolin Decabid Decaderm decamethonium bromide International Nonproprietary Name INN Decapryn Decaspray decimemide International Nonproprietary Name INN decitabine International Nonproprietary Name INN decitropine International Nonproprietary Name INN declenperone International Nonproprietary Name INN Declomycin declopramide International Nonproprietary Name INN decloxizine International Nonproprietary Name INN decominol International Nonproprietary Name INN decoquinate International Nonproprietary Name INN dectaflur International Nonproprietary Name INN deditonium bromide International Nonproprietary Name INN deferasirox United States Adopted Name USAN deferiprone International Nonproprietary Name INN deferitrin United States Adopted Name USAN deferoxamine International Nonproprietary Name INN defibrotide International Nonproprietary Name INN Definity deflazacort International Nonproprietary Name INN deforolimus International Nonproprietary Name INN defosfamide International Nonproprietary Name INN deg deh degarelix International Nonproprietary Name INN dehydrocholic acid International Nonproprietary Name INN dehydroemetine International Nonproprietary Name INN del Del Vi A dela dels delafloxacin United States Adopted Name USAN , International Nonproprietary Name INN Delalutin delanterone International Nonproprietary Name INN delapril International Nonproprietary Name INN Delatestryl delavirdine International Nonproprietary Name INN Delaxin Delcobese delequamine International Nonproprietary Name INN delergotrile International Nonproprietary Name INN Delestrogen delfantrine International Nonproprietary Name INN delfaprazine International Nonproprietary Name INN Delfen Delflex deligoparin sodium United States Adop ... more details
|
- Beta-thalassemia
chelator deferasirox marketed as Exjade by Novartis was approved for use in 2005 in some countries ... more details
|
- Poison
vitamin K opioids naloxone Iron and other heavy metals desferrioxamine , Deferasirox or Deferiprone ... more details
|
- Thalassemia
chelation agent currently approved for use in the United States. Deferasirox Exjade is an oral ... more details
|
- Iron overload
blood transfusions to treat thalassemia and, thus, who develop iron overload as a result are deferasirox ... more details
|
- Binding selectivity
such as deferiprone and deferasirox have been developed, using the known structure of deferoxamine ... more details
|
Encyclopedia
top
